Issue

Vol. 64 No. 1: Issue 1

The undersigned hereby assign all rights, included but not limited to copyright, for this manuscript to CMB Association upon its submission for consideration to publication on Cellular and Molecular Biology. The rights assigned include, but are not limited to, the sole and exclusive rights to license, sell, subsequently assign, derive, distribute, display and reproduce this manuscript, in whole or in part, in any format, electronic or otherwise, including those in existence at the time this agreement was signed. The authors hereby warrant that they have not granted or assigned, and shall not grant or assign, the aforementioned rights to any other person, firm, organization, or other entity. All rights are automatically restored to authors if this manuscript is not accepted for publication.

Circulating prolactin levels and Behcet's disease: A meta-analysis

https://doi.org/10.14715/cmb/2018.64.1.4
Gwan Gyu Song
Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea
Young Ho Lee
Division of Rheumatology, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea

Corresponding Author(s) : Young Ho Lee

lyhcgh@korea.ac.kr

Cellular and Molecular Biology, Vol. 64 No. 1: Issue 1

Abstract

This study aimed to summarize the current evidence on the relationship between circulating prolactin levels and Behcet's disease (BD). We performed a meta-analysis comparing the serum/plasma prolactin levels in patients with BD with those of controls and performed a subgroup analysis based on ethnicity, disease activity, and sex. Ten articles with a total of 320 patients with BD and 259 controls were included. The prolactin levels were not significantly higher in the BD group than in the control group (SMD=0.208, 95% CI=-0.012–0.428, p=0.064). Stratification by ethnicity indicated no elevation in prolactin level in Turkish patients with BD (SMD=0.127, 95% CI=-0.111–0.366, p=0.295). Stratification by disease activity revealed no elevation in prolactin level in both the active and inactive BD groups compared with the control group (SMD=0.373, 95% CI=-0.095–0.841, p=0.119; SMD=0.055, 95% CI=-0.243–0.354, p=0.717). Stratification by sex revealed no elevation in prolactin level in both the female and male BD groups (SMD=0.031, 95% CI=-0.398–0.460, p=0.888; SMD=0.279, 95% CI=-1.411–1.969, p=0.746). The prolactin levels were not significantly elevated in patients with BD, regardless of the adjustments for age/sex, sample size, or data type evaluated. This meta-analysis of current evidence suggests that circulating prolactin levels may not be higher in patients with BD than in controls.

Keywords

Prolactin level Behcet's disease.
Song, G. G., & Lee, Y. H. (2018). Circulating prolactin levels and Behcet’s disease: A meta-analysis. Cellular and Molecular Biology, 64(1), 14–18. https://doi.org/10.14715/cmb/2018.64.1.4
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Engl J Med. 1999;341(17):1284-91.
  2. Appelboom T, Schoutens A. High bone turnover in fibromyalgia. Calcified tissue international. 1990;46(5):314-7.
  3. Vera-Lastra O, Jara LJ, Espinoza LR. Prolactin and autoimmunity. Autoimmun Rev. 2002;1(6):360-4.
  4. Ben-Jonathan N, Mershon JL, Allen DL, Steinmetz RW. Extrapituitary prolactin: distribution, regulation, functions, and clinical aspects. Endocr Rev. 1996;17(6):639-69.
  5. Trott J, Schennink A, Petrie W, Manjarin R, VanKlompenberg M, Hovey R. Prolactin: The multi-faceted potentiator of mammary growth and function1, 2.
  6. Cai Y, Fleming C, Yan J. New insights of T cells in the pathogenesis of psoriasis. Cellular & molecular immunology. 2012;9(4):302-9.
  7. Jara LJ, Medina G, Saavedra MA, Vera-Lastra O, Navarro C. Prolactin and autoimmunity. Clinical reviews in allergy & immunology. 2011;40(1):50-9.
  8. CHAVEZ"RUEDA K, LEGORRETA"HAQUET V, CERVERA"CASTILLO H, Sanchez L, Jara LJ, Zenteno E, et al. Effect of prolactin on lymphocyte activation from systemic lupus erythematosus patients. Annals of the New York Academy of Sciences. 2007;1108(1):157-65.
  9. Mont'Alverne AR, Yamakami LY, Goncalves CR, Baracat EC, Bonfa E, Silva CA. Diminished ovarian reserve in Behcet's disease patients. Clin Rheumatol. 2015;34(1):179-83.
  10. sahIn A, Karakus S, Durmaz Y, Yildiz C, Aydin H, CengIz AK. Ovarian reserve is preserved in Behcet's disease. Int J Rheum Dis. 2015.
  11. Avci A, Avci D. Serum prolactin levels in Behcet's disease. Is there a relationship between Behcet's disease and prolactin as in other autoimmune diseases? Acta Dermatovenerol Croat. 2013;21(1):52-3.
  12. Cil AP, Karabulut AA, Kocak M. Assessment of ovarian stromal artery Doppler characteristics and serum hormone levels in patients with Behcet disease. Diagn Interv Radiol. 2010;16(4):288-92.
  13. Proenca H, Ferreira C, Miranda M, Castanheira-Dinis A, Monteiro-Grillo M. Serum prolactin levels and Behcet disease. Eur J Ophthalmol. 2007;17(3):404-7.
  14. Atasoy M, Karatay S, Yildirim K, Kadi M, Erdem T, Senel K. The relationship between serum prolactin levels and disease activity in patients with Behcet's disease. Cell Biochem Funct. 2006;24(4):353-6.
  15. Apaydin KC, Duranoglu Y, Ozgurel Y, Saka O. Serum prolactin levels in Behcet's disease. Jpn J Ophthalmol. 2000;44(4):442-5.
  16. KarakuÅž S, Nar A, Koçak Toprak S, Atalay F, ć°lhami í–zcebe O. An Evaluation of Hormone Levels in Behçet's Disease. Turkish Journal of Rheumatology. 2012;27(3).
  17. Houman H, Ben GI, Lamloum M, Feki M, Khanfir M, Mebazaa A, et al. Prolactin levels in Behcet's disease: no correlation with disease manifestations and activity. Annales de medecine interne, 2001. 209-11.
  18. Keser G, Oksel F, í–zgen G, Aksu K, Doğanavşargil E. Serum prolactin levels in Behçet's Syndrome. Clinical rheumatology. 1999;18(4):351-2.
  19. Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
  20. Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC medical research methodology. 2014;14(1):135.
  21. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd edn. Hillsdale, New Jersey: L. Erlbaum; 1988.
  22. Egger M, Smith GD, Phillips AN. Meta-analysis: principles and procedures. BMJ. 1997;315(7121):1533-7.
  23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-88.
  24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539-58.
  25. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629-34.
  26. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmunity reviews. 2012;11(6):A465-A70.
  27. Clevenger CV, Russell DH, Appasamy PM, Prystowsky MB. Regulation of interleukin 2-driven T-lymphocyte proliferation by prolactin. Proc Natl Acad Sci U S A. 1990;87(16):6460-4.
  28. Verhelst J, Abs R. Hyperprolactinemia. Treatments in Endocrinology. 2003;2(1):23-32.
Read More
Author biographies is not available.
Crossref
Scopus
Google Scholar
Europe PMC
Download this PDF file
PDF
Statistic
Read Counter : 785 Download : 340